Malaysia-based obesity biotech Medikra files and sets terms for a $20 million US IPO
February 13, 2026 News
Malaysia-based obesity biotech Medikra increases shares offered by 25% ahead of $25 million US IPO
Medikra, a Malaysia-based developer of plant-based bioactives focused on obesity and metabolic syndrome, raised the proposed deal size for its upcoming IPO on Friday.
The Petaling Jaya, Malaysia-based company now plans to raise $25 million by offering 4.5 million shares at a price range of $5 to $6. The company had previously filed to offer 3.6 million shares at the same range. At the midpoint of the revised deal size, Medikra will raise 25% more in proceeds than previously anticipated.
IPO Overview
Medikra, a Malaysia-based developer of plant-based bioactives focused on obesity and metabolic syndrome, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering.
The Petaling Jaya, Malaysia-based company plans to raise $20 million by offering 3.6 million shares at a price range of $5 to $6. At the midpoint of the proposed range, Medikra would command a market cap of $161 million.
Medikra is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade botanical therapeutics. The company advances plant-derived bioactive ingredients into regulated medicines by integrating proprietary botanical extraction, analytical standardization, preclinical and clinical development, and multi-omics （e.g. proteomics and transcriptomics） analysis. Medikra’s lead product candidate, SKF7, is a patented standardized extract of Labisia pumila, a medicinal plant indigenous to Malaysia, under development for the treatment of abdominal obesity and metabolic syndrome. SKF7 has been evaluated in multicenter, randomized, placebo-controlled Phase I and Phase II clinical trials conducted in Malaysia, Indonesia, and India.
The Petaling Jaya, Malaysia-based company was founded in 2006 and plans to list on the NYSE American under the symbol MDKR. Medikra filed confidentially on August 22, 2025. Brookline Capital Markets is the sole bookrunner on the deal.
About the Company
Medikra is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade botanical therapeutics. We advance plant-derived bioactive ingredients into regulated medicines by integrating proprietary botanical extraction, analytical standardization, preclinical and clinical development, and multi-omics （e.g. proteomics and transcriptomics） analysis. Through our wholly owned Malaysian subsidiary, Medika Natura Sdn. Bhd., we have established an end-to-end development platform that bridges traditional botanical knowledge with modern biomedical science, regulatory requirements, and scalable manufacturing. Our lead product candidate, SKF7?, is a patented standardized extract of Labisia pumila, a medicinal plant indigenous to Malaysia, under development for the treatment of abdominal obesity and metabolic syndrome. SKF7? has been evaluated in multicenter, randomized, placebo-controlled Phase I and Phase II clinical trials conducted in Malaysia, Indonesia, and India. Our therapeutic focus extends beyond obesity to include women’s health, chronic inflammation, and oncology, areas where current treatments may be limited by efficacy, safety, or tolerability. We do not position our work as alternative medicine. Rather, we aim to advance evidence-based botanical therapeutics that are developed in alignment with international regulatory standards.